anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The following adverse reactions associated with the use of parenteral phytonadione were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Severe hypersensitivity reactions, including anaphylactoid reactions and deaths, have been reported following parenteral administration. The majority of these reported events occurred following intravenous administration.

Transient "flushing sensations" and "peculiar" sensations of taste have been observed with parenteral phytonadione, as well as instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis.

Hyperbilirubinemia has been observed in the newborn following administration of parenteral phytonadione. This has occurred primarily with doses above those recommended.
The SCD PED-02 trial is examining the safety and efficacy of the Selective Cytopheretic Device (SCD) in treating pediatric acute kidney injury (AKI). Importantly, acute kidney injury is a highly lethal condition in critically ill patients. Despite improvements in acute medical care and advances in dialysis therapies, the mortality rate during the past four decades of this condition has not improved. Critically ill patients with AKI in hospital ICU settings have mortality rates of approximately 50%, including pediatric patients. AKI promotes a systemic inflammatory response syndrome (SIRS) which results in systemic microvascular damage and, if severe, multi-organ dysfunction. Activated circulating leukocytes play a central role in this process. Leukocytes, especially neutrophils, are major contributors to the pathogenesis and progression of many inflammatory disorders, including SIRS, sepsis, ischemia reperfusion injury, and acute respiratory distress syndrome (ARDS). Many therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation to minimize tissue destruction and disease progression.

The SCD is comprised of tubing, connectors, and a synthetic membrane cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and it is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits. The SCD is a synthetic membrane with the ability to bind activated leukocytes and, when used in a continuous renal replacement therapy (CRRT) extracorporeal circuit in the presence of regional citrate anticoagulation, modulates inflammation.

The SCD PED-02 study will test the primary hypothesis that up to ten sequential 24-hour SCD treatments in pediatric patients with AKI will be completed safely and improve survival compared to historical controls who received CRRT alone.
PURPOSE: A cosmetic composition containing Salvia plebeia extract and 3',4',5,6,7-pentahydroxyflavanone is provided to enhance collagen synthesis and to prevent skin aging or wrinkling. CONSTITUTION: Salvia plebeia extract contains 3',4',5,6,7-pentahydroxyflavanone of chemical formula. A cosmetic composition for anti-aging contains the extract as an active ingredient. A cosmetic composition for improving anti-wrinkling contains the extract as an active ingredient. A cosmetic composition for skin whitening contains the extract as an active ingredient. An anti-inflammation or antibacterial cosmetic composition contains the extract as an active ingredient. The cosmetic composition for anti-aging contains the compound as an active ingredient. The cosmetic composition for improving anti-wrinkling contains the compound as an active ingredient. The antibacterial or anti-inflammatory composition contains the compound as an active ingredient.
MBTPS1 (NM_003791.4) encodes Site-1 protease, a serine protease that functions sequentially with Site-2 protease regulating cholesterol homeostasis and endoplasmic reticulum stress response. MBTPS1 pathogenic variants are associated with spondyloepiphyseal dysplasia, Kondo-Fu type (MIM:618392; cataract, alopecia, oral mucosal disorder, and psoriasis-like syndrome, and Silver-Russell-like syndrome). In this report, we describe a 14-year-old female with a complex medical history including white matter volume loss, early-onset cataracts, retrognathia, laryngomalacia, inguinal hernia, joint hypermobility, feeding dysfunction, and speech delay. Additionally, features of ectodermal dysplasia that she has include decreased sweating, heat intolerance, dysplastic nails, chronically dry skin, and abnormal hair growth issues. Exome sequencing analysis identified compound heterozygous variants in the MBTPS1 gene: c.2255G > T p.(Gly752Val) predicted to affect important function of the protein, which was inherited from the mother, and a splice site variant c.2831 + 5G > T, which was inherited from the father. The RNA-seq analysis of the splice variant showed skipping of exon 21, predicted to result in frameshifting p.(Ser901fs28*) leading to non-sense mediated decay. To our knowledge, only eight studies have been published that described the MBPTS1-related disorders. Interestingly, we observed the features of ectodermal dysplasia in our patient that further expands the phenotypic spectrum of MBTPS1 gene-related disorders.
VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
Studies on the CXCL12 rs1801157 polymorphism show that this polymorphism is involved in development of breast cancer, but its specific relationships or effects are not consistent. The purpose of this meta-analysis was to investigate the association between CXCL12 rs1801157 polymorphism and susceptibility to breast cancer. PubMed, Scopus, Embase, the Cochrane Library, Web of Science, and CNKI were searched for eligible studies through February 01, 2023. A total of ten studies with 2093 cases and 2302 controls were included in this meta-analysis. Overall, there is a significant association between CXCL12 rs1801157 polymorphism and risk of breast cancer under the homozygote genetic model (AA vs. GG, OR= 1.350, 95% CI: 1.050-1.734, p= 0.019). Stratified by ethnicity showed a significant association in Caucasian women, but not among Asian and mixed populations. This meta-analysis confirms that CXCL12 rs1801157 polymorphism is related to breast cancer risk, especially among Caucasian women. However, well-designed large-scale studies are required to further evaluate the results.
PROBLEM TO BE SOLVED: To obtain a medicine, comprising a flavonoid compound having the aurone skeleton as an active ingredient and having suppressing actions on the Maillard reaction. SOLUTION: This suppressant for the Maillard reaction comprises a flavonoid compound represented by formula I, preferably maritimein represented by formula II or its salt or sulfuretin represented by formula III or its salt as an active ingredient. The suppressant for the Maillard reaction is useful for preventing and treating diseases caused by the Maillard reaction, diabetes and complications thereof, e.g. neurosis, cerebral angiopathy, peripheral circulation disorder, coronary arterial cardiopathy, arteriosclerosis, arthrosclerosis, cataract or retinopathy or diseases caused by aging, e.g. senile cataract, atherosclerosis, coronary arterial cardiopathy or cerebral angiopathy. The daily dose thereof for an adult is 10mg to 10g perorally or parenterally administered. The compounds of formula II and III are well known and usually available.
Celecoxib exhibits dose-proportional increase in exposure after oral administration up to 200 mg twice daily and less than proportional increase at higher doses. It has extensive distribution and high protein binding. It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.

Absorption 

  
Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Under fasting conditions, both peak plasma levels (C max) and area under the curve (AUC) are roughly dose-proportional up to 200 mg twice daily; at higher doses there are less than proportional increases in C max and AUC [see Food Effects]. Absolute bioavailability studies have not been conducted. With multiple dosing, steady- state conditions are reached on or before Day 5. The pharmacokinetic parameters of celecoxib in a group of healthy subjects are shown in Table 4.
The invention relates to novel materials based on biodegradable homopolyamino acids and which can be used for the vectorization of (an) active ingredient(s) (AI). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitaty compositions based on homopolyamino acids. The invention can produce a novel polymer raw material which can be used for the vectoiization of Al that can optimally be: biocompatible, biodegradable, capable of becoming easily associated with a large number of active ingredients or solubilizing them and releasing the active ingredients in vivo. According to the present invention, which primarily relates to linear homopolyamino acids having aspartic or glutamic units and whose attachments can include hydrophobic groups having 8-30 carbon atoms. The homopolymers are amphiphilic and anionic and can easily be transformed at low cost into particles for the vectorization of active ingredients. The particles can form stable aqueous colloidal suspensions.
Technologies are generally described for normalized standard deviation transition based dosimetry monitoring for laser treatment. In some examples, a response signal may be generated based on a physical response to a laser pulse detected through acoustic or optical means. Each response signal may be a time series of data with a number of points. Standard deviation may be determined for each response signal and normalized using a mean or comparable normalization factor. Thus, a robust distribution may be computed from the response to each laser pulse. A change in the normalized standard deviation from each single pulse's time domain response data may be used to determine how many laser pulses remain before completion of the treatment (similar to event onset response). Thus, laser treatment may be continued based on an estimation of remaining pulses for completion or ceased if completion is reached.
Up to 60% of older persons with Alzheimer's disease and related dementias (ADRD) suffer from bothersome pain and nearly half experience pain-related activity limitations. Despite best-practice guidelines calling for routine pain assessment of persons with ADRD, pain is severely under-detected and poorly managed in this population. A major barrier to the identification and treatment of pain in persons with ADRD is impaired communication. Informal (family) caregivers are well situated to detect pain and facilitate management in persons with ADRD, given their extensive involvement in care activities. However, caregivers receive virtually no guidance or training in these areas. The Pain Identification and Communication Toolkit (PICT) is a multicomponent intervention for ADRD caregivers that provides training in observational pain assessment and coaching in effective pain communication techniques. PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist. This project aims to (1) determine the efficacy of PICT compared with an Attention Control (AC) condition, (2) identify the patient and caregiver factors that may moderate the effects of PICT on study outcomes, and (3) evaluate the mechanisms (theoretically-derived variables) by which PICT affects study outcomes. Participants will be recruited from programs of all-inclusive care for the elderly (PACE) programs and partnering health care clinics. They will complete assessments at 0 (baseline), 1, 3, and 6 months.
The present invention relates to a compound superfine powder of a copper-zinc compound having the performance of anti fouling, antibacterium and mould proofing, and a preparation process and a purpose thereof. The compound superfine powder solves the defects that a single copper compound only can prevent fouling and resist algae, and a zinc compound only can prevent mildew. A technical scheme comprises: the compound superfine powder of a copper-zinc compound has a core shell type structure. The preparation process comprises: a colloidal particle of a superfine copper compound is first prepared, and then, the precipitation of a zinc compound is generated at the surface of a crystal seed to form the compound superfine powder of a copper-zinc compound by using the colloidal particle as the crystal seed under the condition that a macromolecule protecting agent is added. The preparation process can also be as follows: the surface of a colloidal particle of a copper compound can be partially or fully coated with the zinc compound, or the compound superfine powder of a copper-zinc compound is formed by coating in a reverse mode when the copper compound and the zinc compound are together deposited in a solution according to the relation of the zeta potential of the colloid of the copper compound and the colloid of the zinc compound. The compound superfine powder can be directly used as an antifouling agent, a mouldproof agent, an algae resistant agent and an antibacterial agent, and can also be applied to the fields of plastics, nylon, paint, fabrics, rubber, ceramics, etc. to be prepared into a material with the functions of mould proofing performance, anti-fouling performance, algae resistance, etc.
In double mild stimulation protocol, Clomiphene citrate 25 mg/day (Ovumid®; Iran Hormone pharmaceutical Co., Iran) and co-treatment with letrozole 2.5 mg/day (Femati®, Atipharmed Co., Iran) will be given from cycle day 3. Letrozole is given for 4 days and clomiphene citrate is used daily before the trigger day. Patients take 150 IU of Human menopausal gonadotropin (HMG) (Humegnan®, Darou Pakhsh Co., Iran) every other day beginning on cycle day 6. When one dominant follicle will reach 18 mm, the ﬁnal triggering will induce 34-36 h after 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) administration. In luteal phase stimulation a total of 225 IU HMG and letrozole 2.5 mg will administered daily from3 to 5 days after oocyte retrieval. Letrozole administration will be stopped when the dominant follicles reached 12 mm. When one dominant follicle will reach 18 mm, the ﬁnal triggering will be induced with 0.5 cc of Buserelin acetate.
Nasal Spray of placebo liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. fMRI scan pre and post-administration.
BACKGROUND: Inadequate access to affordable, safe, desirable and convenient nutrient-dense food is one of the underlying causes of child stunting. While targeted nutrition-sensitive interventions (eg, backyard 'nutri-gardens') may increase dietary diversity within farming households, such interventions have limited scalability across the wider food system where markets remain underdeveloped. This research aims to develop and assess market-based interventions for key nutrient-dense foods to help improve the diets of women and children in the first 1000 days of life.
METHODS: Data collection uses four parallel approaches in each of the three study countries (India, Indonesia and Senegal). (1) A novel food environment tool will be developed to characterise the accessibility and affordability of nutrient-dense foods in the study countries. The tool will be validated through pretesting using cognitive interviewing and piloting in purposively sampled households, 10 (cognitive interviewing) and 30 (piloting) households in each country; (2) stakeholder interviews (eg, with producers, intermediaries and retailers) will be conducted to map out nutrition-sensitive entry points of key value chains (eg, animal-sourced foods), before hotspots of potential food safety hazards will be identified from food samples collected along the chains; (3) the Optifood and Agrifood tools will be used to identify foods that can address food system nutrient gaps and engage key stakeholders to prioritise market interventions to improve nutrition outcomes. Optifood and Agrifood parameters will be informed by publicly available data, plus interviews and focus groups with value chain stakeholders; (4) informed by the previous three approaches and a campaign of participatory 'group model building', a novel system dynamics model will evaluate the impact of alternative market-based solutions on the availability and affordability of nutrient-dense foods over time.
ETHICS AND DISSEMINATION: The study has received ethical approval in the United Kingdom, Senegal, Indonesia and India. Dissemination comprises peer-reviewed journals, international disciplinary conferences and multistakeholder dissemination workshops.
One million patients attend Emergency Departments (ED) with head injuries each year in the United Kingdom (UK) and Ireland. 150,000 of these patients will need hospital admission and one study estimates an incidence of 45-48% moderate or severe disability in those surviving admission. Although the incidence of head injury is high, the incidence of death from head injury is low. Therefore ED's are required to see a large number of patients with a minor/mild head injury, and identify the very small number of these that will go on to have serious complications. The challenge to the emergency medicine clinician is identifying which patients with a head injury have an important brain injury that requires further attention and which patients can be safely sent home. The standard for determining an important brain injury is the result on the Computerised Tomography (CT) scan of the head. CT scanning is nonportable and exposes individuals to high radiation levels.

The study medical device is a portable, point of care, noninvasive and non radiation-emitting medical device designed to assist clinicians in early identification, staging, and optimisation of treatment for patients who are head injured.
BACKGROUND: Papillary thyroid cancer (PTC) is the most prevalent histological type of differentiated thyroid malignancy. Circular RNAs (circRNAs) have been implicated in the pathogenesis and progression of various cancers. circTIAM1 (hsa_circ_0061406) is a novel circRNA with aberrant expression in PTC. However, its functional roles in PTC progression remain to be investigated.
METHODS: The expression levels of circTIAM1 in the PTC and the matched para-cancerous tissues were detected by quantitative real-time reverse-transcription PCR (qRT-PCR). The subcellular localization of circTIAM1 was examined by fluorescence in-situ hybridization (FISH). Kaplan-Meier plot was used to analyze the association of clinicopathological features with circTIAM1 expression. Bioinformatics databases were utilized to predict the target miRNAs of circTIAM1 and the downstream target mRNAs. RNA pull-down, RIP assay, and dual-luciferase reporter assay were used to confirm the interactions. Functional experiments, such as CCK-8, EDU staining, and apoptosis assays, as well as in vivo xenograft model were employed to explore the impacts of circTIAM1, miR-338-3p, and LIM/SH3 protein 1 (LASP1) on the malignant phenotype of the PTC cells.
RESULTS: CircTIAM1 was highly expressed in PTC cells. Moreover, circTIAM1 silencing suppressed the proliferation and invasion of PTC cells in vitro and impaired tumorigenesis in vivo. Furthermore, miR-338-3p was verified as a miRNA target of circTIAM1. LASP1 was also identified as a downstream target of miR-338-3p. The anti-tumorigenic effect of miR-338-3p overexpression and the pro-tumorigenic effect of LASP1 was further explored by functional assays, which demonstrated that circTIAM1 modulated the PTC progression through targeting miR-338-3p/LASP1 axis.
CONCLUSION: The overexpression of circTIAM1 is associated with the malignant progression of PTC. A high level of circTIAM1 promotes the malignancy of PTC cells via the miR-338-3p/LASP1 axis.
1. A Pharmaceutical composition in a form suitable for parenteral administration comprising a solution of (E)-3-[2-(phenylcarbamoyl) ethenyl]-4,6-dichloroindole-2-carboxylic acid or a physiologically acceptable salt thereof, in an isotonic sugar solution containing a water miscible organic solvent for the compound, said formulation having a pH within the range of 7 to 9. 2. A pharmaceutical composition as claimed in Claim 1 having a pH in the range 8.0 to 9.0. 3. A pharmaceutical composition as claimed in Claim 1 or Claim 2 wherein pH is adjusted or maintained by means of a suitable buffer salt. 4. A pharmaceutical composition as claimed in Claim 3 wherein the buffer salt is tris(hydroxymethyl) aminomethane. 5. A pharmaceutical composition as claimed in any of Claims 1 to 4 in a form suitable for intravenous infusion. 6. A pharmaceutical composition as claimed in Claim 5 containing ethylene diamine tetra acetic acid and or a physiologically acceptable salts thereof. 7. A pharmaceutical composition as claimed in Claims 5 or 6 wherein the concentration of the glycine antagonist (expressed in terms of the free acid) is within the range 0.5 to 2mg/ml. 8. A pharmaceutical composition as claimed in any of Claims 5 to 7 wherein the water miscible organic solvent is propylene glycol. 9. A pharmaceutical composition as claimed in any of Claims 5 to 8 wherein the isotonic sugar solution is an aqueous dextrose solution. 10. A pharmaceutical composition as claimed in any of Claims 1 to 4 in a form suitable for administration as a bolus injection. 11. A pharmaceutical composition as claimed in Claim 10 wherein the concentration of the glycine antagonist (expressed in terms of the free add) is within the range 10 to 80 mg/ml. 12. A pharmaceutical composition as claimed in Claims 10 or 11 wherein the water miscible organic solvent is glycofurol. 13. A pharmaceutical composition as claimed in any of Claims 10 to 12 wherein the sugar solution is aqueous mannitol. 14. A pharmaceutical composition as claimed in any of Claims 10 to 13 containing a surfactant. 15. A pharmaceutical composition as claimed in any of Claims 1 to 14 wherein the composition is prepared using the sodium salt of (E)-3-[2-(phenylcarbamoyl) ethenyl]-4, 6-dichloroindole 2-carboxylic add.